Oral agents and Outpatient Injections
FUNDING:
CancerCare Manitoba covers in- and outpatient cost of injectable and oral treatments no matter where they are taken. Certain drugs or other items are approved for coverage under the Exception Drug Status (EDS) Program when they meet specific criteria and upon review and recommendation of the Manitoba Drug Standards and Therapeutics Committee (MDSTC).
FORMULARIES:
Manitoba Drug Benefits: Click Here
Formulary Lookup: Click Here
Bulletin Archive: Click Here
Manitoba Home Cancer Drug Program: Click Here
Drug (Brand Name) Manufacturer |
Indication | Strength, Route | DIN | Provincial Funding Eligibility Criteria | References | Patient Assistance Programs |
---|---|---|---|---|---|---|
Abiraterone (Zytiga) Janssen Inc. Generic | mCRPC | 250 mg Tab, 500 mg Tab |
Multiple1 |
Exceptional Drug Status (EDS) Benefits – Part 3 Benefits: will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis2 Eligibility2: For patients with histologically confirmed mCRPC with disease progression after prior ADT or with disease progression after prior chemotherapy with docetaxel |
Janssen (Janssen BioAdvance Patient Assistance Program): Access Here |
|
Abiraterone (Zytiga) Janssen Inc. Generic | mCSPC | 250 mg Tab, 500 mg Tab |
Multiple1 |
Exceptional Drug Status (EDS) Benefits – Part 3 Benefits: will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis1 Eligibility1:
|
|
Janssen (Janssen BioAdvance Patient Assistance Program): Access Here |
Alendronate Generic | Not Specified | 10 mg Tab, 70 mg Tab |
Multiple1 |
Part 1 Benefit – no therapeutic criteria attached to the benefit1 |
|
- |
Apalutamide (Erleada) Janssen Inc. | nmCRPC | Tablet, PO, 60mg, 240mg |
02478374 |
Exceptional Drug Status (EDS) Benefits – Part 3 Benefits: will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis1 Eligibility1:
**60 mg tablet funded, 204 mg table pending provincial funding decision. |
Janssen BioAdvance Patient Assistance Program: Access Here |
|
Apalutamide (Erleada) Janssen Inc. | mCSPC | Tablet, PO, 60mg, 240mg |
02478374 |
Exceptional Drug Status (EDS) Benefits – Part 3 Benefits: will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis1 Eligibility1:
**60 mg tablet funded, 204 mg table pending provincial funding decision. |
|
Janssen BioAdvance Patient Assistance Program: Access Here |
Darolutamide (Nubeqa) Bayer | nmCRPC | 300 mg Tab |
02496348 |
Exceptional Drug Status (EDS) Benefits – Part 3 Benefits: will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis1 Eligibility1:
|
NUBEQA® DART Patient Support Program: Toll free: 1-833-955-3278 Fax: 1-877-208-4393 Email:
|
|
Darolutamide (Nubeqa) Bayer | mCSPC | 300 mg Tab |
02496348 |
Exceptional Drug Status (EDS) Benefits: Will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis Criteria:
|
NUBEQA® DART Patient Support Program: Toll free:1-833-955-3278 Fax:1-877-208-4393 Email: info@dartsupport.ca |
|
Denosumab (Prolia) Amgen | Osteoporosis | 60 mg/ml Injection |
02343541 |
Exceptional Drug Status (EDS) Benefits – Part 3 Benefits: will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis1 Eligibility:
Notes:
|
|
ProVital Program: Access Here |
Denosumab (Prolia) Amgen | mCRPC + Bone mets | 120 mg Injection |
02368153 |
Exceptional Drug Status (EDS) Benefits – Part 3 Benefits: will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis1
|
|
The VICTORY Program: Access Here |
Enzalutamide (Xtandi) Astellas | mCRPC | 40 mg Cap |
02407329 |
Exceptional Drug Status (EDS) Benefits – Part 3 Benefits: will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis1 Eligibility:
|
|
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (French)
|
Enzalutamide (Xtandi) Astellas | nmCRPC | 40 mg Cap |
02407329 |
Exceptional Drug Status (EDS) Benefits – Part 3 Benefits: will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis1 Eligibility1:
|
|
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (French)
|
Enzalutamide (Xtandi) Astellas | mCSPC | 40 mg Cap |
02407329 |
Exceptional Drug Status (EDS) Benefits – Part 3 Benefits: will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis1 Eligibility:
|
|
Expedite® Patient Assistance Program: Access Here |
Niraparib and abiraterone acetate (AKEEGA®) Janssen Inc. | mCRPC | Dual-action tablet, PO/ Comprimé à double action, PO: 100mg niraparib/500mg abiraterone acetate |
02538563 |
Pending provincial funding decision |
N/A |
Janssen BioAdvance Patient Assistance Program: Access Here |
Olaparib (Lynparza) AstraZeneca | mCRPC | 100 mg tab | 150 mg tab |
100mg: 02475200 | 150mg: 02475219 |
|
|
AstraZeneca Patient Support Program: Access Here |